European Biopharmaceutical Review |
 |
|
|
|
|
 |
| |
|
|
|
|
The Secret Sauce
Practical and effective lipid nanoparticles are the critical enabling innovation making mRNA-based vaccines a practical reality. EBR Industry Advisor, Emile Bellott, looks at the background of this important advance in materials science and drug delivery
|
|
|
|
|
Down the Rabbit Hole: Navigating the Functional Genomics Funnel
Benjamin Borgo at Merck
The power to edit genomes at any scale has revolutionised drug discovery through the ability to create far truer representations of human biology than have ever been available
|
|
|
|
The Route to Sustainable Procurement
George I’ons at Owen Mumford Pharmaceutical Services
How the biopharmaceutical industry is taking environmental responsibility head-on and forging a path towards a sustainable tomorrow
|
|
|
|
|
Overcoming Challenges in Orphan Drug Development
Rachel Smith at Veristat
While there is no ‘out-of-the-box’ roadmap for orphan drug development, through a toolkit of innovative solutions, we can address the unique aspects of clinical development in rare diseases, upfront
|
|
|
|
Advancing Affordable Orphan Drug Development
Haishan Jang at BRIM Biotechnology
Haishan Jang, CEO at BRIM Biotechnology, reveals the biggest challenges of orphan drug development and the significant breakthroughs that are helping the pursuit of innovation
|
|
|
|
Special Delivery
Sonya Montgomery at Evox Therapeutics
EBR sits down with Sonya Montgomery, Chief Medical Officer at Evox Therapeutics, to discuss how the power of exosomes can be harnessed to overcome the delivery issues in orphan drug development
|
|
|
|
|
Diagnostics Leads the Fight Against Antimicrobial Resistance
François Lacoste at bioMérieux
While COVID-19 has been under a spotlight in the last year and a half, the threat of antimicrobial resistance remains critically urgent. Diagnostics could be pivotal in the development of effective solutions and to preserve antibiotic efficacy for future generations
|
|
|
|
We Are Losing Our Strongest Allies Against Infectious Diseases
Alexander Sturm at Resistell
Antibiotic resistance and antibiotic tolerance are hindering our ability to slow the spread of infectious diseases, and the trends show that this may only be the start of the problem
|
|
|
|
A Multifaceted Global Approach to Addressing Antimicrobial Resistance
Caroline Forkin at ICON
In a world threatened by AMR, prospects for improving diagnosis, treatment, and prevention could lie in global awareness and collaboration
|
|
|
|
|
Accelerating Biosimilars
Georg Feger at Fresenius Kabi
To ensure patients continue to experience the benefit of biosimilars, a solution to accelerate access will be vital in helping healthcare systems address some of their most critical challenges
|
|
|
|
Elevate Your Biosimilars Through Branding
Nancy Globus, Manfred Weiler, Justin Holloway, Phil Ford, Andreas Reinbolz, and Jamie Cobb at Syneos Health
When it comes to biosimilars, saying that you are the same is not enough, and the sector is waking up to the realisation that simply offering a lower price is not the effortless road to riches it once may have seemed
|
|
|
|
Structural Analytical Challenges in Biosimilar and Generic Drug Development
Richard Easton at BioPharmaSpec
The chemistry we perform on biologic molecules to tailor them for our own needs gives rise to challenges in structural analysis that will require technology, experience, and tools to structurally dissect these different classes of drugs
|
|
|
|
|
Regenerative Immunology: A New Era for the Treatment of Autoimmune Conditions
Giovanni Amabile at Enthera Pharmaceuticals
Inflammatory bowel disease and Type 1 diabetes are two autoimmune conditions that could benefit from a new regenerative medicine to rehabilitate specific pathways
|
|
|
|
Probing Models of Neurological Disease in a Dish Using Multielectrode Arrays
James Ross at Axion BioSystems
Using induced pluripotent stem cells differentiated into neurons that recapitulate diseases, such as ALS and epilepsy, researchers are opening new doors for scientists to model and treat neurological diseases
|
|
|
|
|
Welcome to the BIO-Europe® Digital 2021 Supplement in association with European Biopharmaceutical Review
Pam Putz at EBD Group
|
|
|
|
Embracing Diagnostics to Hinder Antimicrobial Resistance
Chelsea Brooks at Sysmex Europe
Since the invention of groundbreaking antibiotics, such as penicillin, we have ignored the warning signs that lead to antimicrobial resistance, but it is hoped that new diagnostic tools can add to our growing armamentarium
|
|
|
|
Innovative Technology Revolutionises Vaccine Development
BioCopy
With vaccine development under the microscope, BioCopy discusses its new molecular copier technology, which offers effective and, above all, fast protection against upcoming pandemics and rapidly changing virus strains
|
|
|
|
Next-Generation Treatments to Cure Chronic Diseases
Evotec
|
|
|
|
Pruning the Branches of Rare Cancer
Johanna Bendell at Roche
Oncology patients are faced with universal treatments that often fail to truly understand the complexity of each individual strain of cancer. Professors and doctors from around the world discuss the importance of orphan drugs to suit each disease and every person
|
|
|
|
The Potential of Pluripotent Stem Cells for ‘Off-the-Shelf’ Cell Therapy
Alessandra De Riva and Eirini Koutsouraki at Mogrify
Human pluripotent stem cells are characterised by their undifferentiated status, infinite self-renewal capacity, and ability to differentiate into any cell type in the body. These characteristics make them an appealing source for therapeutic applications, from regenerative therapy to immuno-oncology
|
|
|
|
Richter-Helm – The CDMO to Match Your Needs
Richter-Helm
One step ahead – biopharmaceutical production capacity enlargement
|
|
|
|
|
|
